MOS Prebiotic Potential in Older Adults

N/AActive Not RecruitingNCT05939336

University of Florida40 enrolled

Overview

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Mannooligosaccharides yeast extractDIETARY_SUPPLEMENT

15 g per day of mannooligosaccharide yeast extract.

Eligibility

Sex: ALLMin age: 50 YearsMax age: 99 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adults 50-99 years of age. * Able to provide written informed consent in English. * Willingness to complete all study procedures * Healthy or diagnoses with Parkinson's or multiple system atrophy Exclusion Criteria: * Yeast allergy. * Self-reported kidney disease. * Elite athletes or long-distance runners. * Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit. * Current use of laxatives or antidiarrheal medications. * Use of other investigational products within 3 months of the screening visit. * Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report). * Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection) * Current cancer treatment * Currently pregnant

Locations (1)

Food Science and Human Nutrition Department, University of Florida

Gainesville, Florida, United States

Outcomes

Primary Outcomes

Mean daily rating of gastrointestinal symptoms

Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.